Comparing the Immunogenicity of AS03-Adjuvanted 2009 Pandemic H1N1 Vaccine with Clinical Protection in Priority Risk Groups in England

Yung, Chee-Fu; Andrews, Nick; Hoschler, Katja; Miller, Elizabeth
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
In England, during pandemic 2009 H1N1, vaccine efficacy and immunogenicity population studies in priority groups were rolled out in parallel to evaluate the pandemic vaccination programme. This provided a unique opportunity to compare immunogenicity and clinical protection in the same population and thus provide insights into the correlates of protection for the pandemic H1N1 2009 vaccine in risk groups. While clinical protection from AS03-adjuvanted pandemic 2009 H1N1 vaccine was high in those aged <25 years and pregnant women, effectiveness in older adults with chronic conditions has been found to be surprisingly poor. Here we present results from the immunogenicity study derived from the same population. Individuals from priority groups eligible for pandemic vaccination attending participating general practices were recruited. Pre and post-vaccination blood samples were collected and HI antibody testing to assess immune response to vaccination performed. The final cohort consisted of 610 individuals: 60 healthy children aged <5 years; 32 healthy pregnant women; 518 individuals from risk groups. Seroconversion rate in healthy children aged <5 years (87%, 95% CI: 75% to 94%) was higher than that of risk groups combined (65%, 95% CI: 61% to 69%) (p<0.001). Multivariable analysis of risk groups showed that the size of response in those who did seroconvert was lower in those who received the 2009/10 seasonal TIV (Fold effect: 0.52, 0.35 to 0.78). Predicted immunological boosting from higher pre-vaccine titres after 2009 pandemic H1N1 vaccination only occurred in children (seroconversion rate = 92%) and not in individuals aged 10 to 39 from risk groups (seroconversion rate = 74%). The lack of clinical protection identified in the same population in older adults from risk groups could be attributed to these lower seroresponses. Current immunogenicity licensing criteria for pandemic influenza vaccine may not correlate with clinical protection in individuals with chronic disease or immunocompromised.


Related Articles

  • Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak. Openshaw, P J M; Dunning, J // Mucosal Immunology (1933-0219);Sep2010, Vol. 3 Issue 5, p422 

    In this article the authors discuss the lessons that they have learned during the outbreak of the pandemic (H1N1) influenza virus on 2009. The authors discover that the virus is only a mild infection which brought severe diseases to people due to the combination of host genotype and the virus...

  • Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 Influenza pandemic. Magalhaes, Isabelle; Eriksson, Mikael; Linde, Charlotte; Muhammad, Rashid; Rane, Lalit; Ambati, Aditya; Axelsson-Robertson, Rebecca; Khalaj, Bahareh; Alvarez-Corrales, Nancy; Lapini, Giulia; Montomoli, Emanuele; Linde, Annika; Pedersen, Nancy L.; Maeurer, Markus // BMC Infectious Diseases;2014, Vol. 14 Issue 1, p1 

    Background Previous exposures to flu and subsequent immune responses may impact on 2009/2010 pandemic flu vaccine responses and clinical symptoms upon infection with the 2009 H1N1 pandemic H1N1 influenza strain. Qualitative and quantitative differences in humoral and cellular immune responses...

  • Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant. Ferguson, Murdo; Risi, George; Davis, Matthew; Sheldon, Eric; Baron, Mira; Ping Li; Madariaga, Miguel; Fries, Louis; Godeaux, Olivier; Vaughn, David // Journal of Infectious Diseases;3/1/2012, Vol. 205 Issue 5, p733 

    Background. In this study (NCT00985088) we evaluated different formulations of an H1N1 2009 pandemic influenza vaccine that deliver various viral hemagglutinin (HA) doses with or without AS03 (a tocopherol-based oil-in-water adjuvant system). Methods. A total of 1340 healthy subjects aged...

  • Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk. Vaarala, Outi; Vuorela, Arja; Partinen, Markku; Baumann, Marc; Freitag, Tobias L.; Meri, Seppo; Saavalainen, Päivi; Jauhiainen, Matti; Soliymani, Rabah; Kirjavainen, Turkka; Olsen, Päivi; Saarenpää-Heikkilä, Outi; Rouvinen, Juha; Roivainen, Merja; Nohynek, Hanna; Jokinen, Jukka; Julkunen, Ilkka; Kilpi, Terhi // PLoS ONE;Dec2014, Vol. 9 Issue 12, p1 

    Background: Narcolepsy results from immune-mediated destruction of hypocretin secreting neurons in hypothalamus, however the triggers and disease mechanisms are poorly understood. Vaccine-attributable risk of narcolepsy reported so far with the AS03 adjuvanted H1N1 vaccination Pandemrix has...

  • Flu vaccination campaign poses monitoring difficulties. Collier, Roger // CMAJ: Canadian Medical Association Journal;10/13/2009, Vol. 181 Issue 8, pE163 

    The article offers information on the monitoring difficulties posed by the Flu vaccination campaign. According to the provincial health officer for British Columbia Dr. Perry Kendall, H1N1 infection is a complicate matters as few people will have H1N1 infections by getting the vaccine or few...

  • Knowledge, attitudes and anxiety towards influenza A/H1N1 vaccination of healthcare workers in Turkey. Savas, Esen; Tanriverdi, Derya // BMC Infectious Diseases;2010, Vol. 10 Issue 1, p281 

    Background: This study aimed to analyze the factors associated with knowledge and attitudes about influenza A (H1N1) and vaccination, and possible relations of these factors with anxiety among healthcare workers (HCW). Methods: The study used a cross-sectional descriptive design, and it was...

  • Exciting advances in immunisation. Taylor, Lynn // New Zealand Doctor;2/9/2011, p25 

    The article discusses the highlights of the Ninth Canadian Immunisation Conference hosted by the Public Health Agency of Canada in Quebec in December 2011. The four-day programmed discussed several topics that included H1N1 influenza, human papillomavirus (HPV), and invasive pneumococcal disease...

  • Untitled.  // Biomedical Market Newsletter;12/20/2010, p442 

    The article news briefs related to diseases in the U.S. Public health messages should be circulated through television, focusing on the risks and benefits of receiving the 2009 H1N1 vaccine, to increase its coverage. School districts and health departments should provide families with reasons...

  • IN THE NEWS: DO WE NEED FLU SHOTS? J. P. // Baby Talk;Aug2010, Vol. 75 Issue 6, p48 

    The article presents the release of the universal recommendation from the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices for adults on H1N1 flu virus, which means that the whole U.S. population are boosted to get vaccinated.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics